CN110846253A - Bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicine - Google Patents
Bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicine Download PDFInfo
- Publication number
- CN110846253A CN110846253A CN201911164456.0A CN201911164456A CN110846253A CN 110846253 A CN110846253 A CN 110846253A CN 201911164456 A CN201911164456 A CN 201911164456A CN 110846253 A CN110846253 A CN 110846253A
- Authority
- CN
- China
- Prior art keywords
- jybr
- bifidobacterium lactis
- immunity
- food
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 138
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 137
- 235000013305 food Nutrition 0.000 title claims abstract description 31
- 230000036039 immunity Effects 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 23
- 238000004321 preservation Methods 0.000 claims abstract description 20
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 9
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 8
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 238000009629 microbiological culture Methods 0.000 claims abstract description 5
- 210000001539 phagocyte Anatomy 0.000 claims abstract description 5
- 230000028327 secretion Effects 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims description 57
- 239000007788 liquid Substances 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 36
- 239000001963 growth medium Substances 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 7
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 235000015278 beef Nutrition 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- 229910052564 epsomite Inorganic materials 0.000 claims description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 2
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 2
- 239000001393 triammonium citrate Substances 0.000 claims description 2
- 235000011046 triammonium citrate Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 229940127557 pharmaceutical product Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 abstract description 15
- 230000004727 humoral immunity Effects 0.000 abstract description 9
- 230000007969 cellular immunity Effects 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 230000003832 immune regulation Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 35
- 210000000952 spleen Anatomy 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 241000186000 Bifidobacterium Species 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 239000000725 suspension Substances 0.000 description 18
- 210000004989 spleen cell Anatomy 0.000 description 16
- 239000006285 cell suspension Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000008055 phosphate buffer solution Substances 0.000 description 14
- 230000002949 hemolytic effect Effects 0.000 description 12
- 238000012258 culturing Methods 0.000 description 11
- 241000186660 Lactobacillus Species 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 229930003270 Vitamin B Natural products 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 235000019156 vitamin B Nutrition 0.000 description 8
- 239000011720 vitamin B Substances 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000305071 Enterobacterales Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241001156739 Actinobacteria <phylum> Species 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241001134770 Bifidobacterium animalis Species 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- 102000016918 Complement C3 Human genes 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- GXOMMGAFBINOJY-SLINCCQESA-M dicloxacillin sodium Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl GXOMMGAFBINOJY-SLINCCQESA-M 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010028778 Complement C4 Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000194035 Lactococcus lactis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000000214 effect on organisms Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- -1 lysine amino acid Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000005201 spleen development Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a microbial strain, in particular to bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicines, and the invention provides bifidobacterium lactis JYBR-190 with the preservation number as follows: CGMCC NO.18092, the preservation date is 7/8 2019, the preservation unit is China general microbiological culture Collection center, and the preservation address is as follows: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North; the immune regulation effect of the bifidobacterium lactis JYBR-190 on organisms mainly comprises two aspects of humoral immunity and cellular immunity, and particularly, the bifidobacterium lactis JYBR-190 has the effects of activating NK (natural killer) cells and phagocytic cells and improving erythrocyte immunoadhesion, so that the immunity of the organisms is improved through humoral immunity, the activated proliferation and secretion of B lymphocytes are improved, the immunity of the organisms is improved through cellular immunity, and the immunity of the organisms of people can be effectively improved.
Description
Technical Field
The invention relates to a microbial strain, in particular to bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicines.
Background
Bifidobacterium lactis, also called Bifidobacterium animalis (Bifidobacterium), is one of the predominant bacteria in the intestinal tract of humans and many mammals. Can synthesize vitamins B1, B2, B6, etc. in human intestinal tract, can be slowly absorbed by human body, can secrete multiple enzymes to promote degradation and absorption of food, can ferment lactose to produce galactose, and can improve the utilization rate of lactose intolerance patients to dairy products.
With the continuous deterioration of living environment, bacteria and viruses often cause diseases, such as cold, tracheitis, pneumonia, gastroenteritis and the like, the diseases are not highly infectious, but cannot be completely isolated from life, and generally can not change the life of people, and the diseases are also often generated in weak-resistance people, such as old people, children and postoperative people. At present, people can supplement medicines or foods for improving body resistance in order to reduce the incidence of diseases, and the foods are not completely suitable for old people, children and postoperative people.
At present, most of foods for improving the body resistance are nutritional products or Chinese medicinal materials purchased in drugstores, and the foods have poor effect on improving the body immunity and often have no ideal effect.
Disclosure of Invention
The invention provides bifidobacterium lactis JYBR-190, which has the effects of improving the activity of NK cells and phagocytes and improving the immune adhesion of erythrocytes, so that the immunity of the organism is improved through humoral immunity, the activated proliferation and secretion of B lymphocytes are improved, the immunity of the organism is improved through cellular immunity, the immunity of a human body can be effectively improved, and the occurrence of diseases is reduced.
The invention provides bifidobacterium lactis JYBR-190 capable of improving human immunity, wherein the bifidobacterium lactis has the preservation number: CGMCC NO.18092, the preservation date is 7/8/2019, the strain is named as JYBR-190, the preservation unit is China general microbiological culture Collection center, the preservation address is as follows: west road No.1, north chen, chaoyang district, beijing, zip code: 100101.
the invention also aims to provide application of the bifidobacterium lactis JYBR-190 capable of improving human immunity in preparation of food and medicines
Furthermore, the food and the medicine are applied to the food for improving the immunity of the organism.
Further, the food and the medicine are preserved with the preservation number as follows: the Bifidobacterium lactis JYBR-190 with the molecular weight of CGMCC NO.18092 is prepared.
Furthermore, the food and the medicine have the functions of improving the activity of NK cells and phagocyte cells, improving the immunoadhesion of erythrocytes and improving the activation, proliferation and secretion of B lymphocytes.
Further, the food and the medicine comprise bifidobacterium lactis JYBR-190 freeze-dried powder.
Further, the preparation method of the bifidobacterium lactis JYBR-190 freeze-dried powder comprises the steps of inoculating 1% of bifidobacterium lactis strains into 99% of MRS liquid culture medium, carrying out anaerobic culture at 37 ℃ for 24 hours, taking MRS bacterial liquid, centrifuging and freeze-drying to obtain bacterial powder, adding isomaltooligosaccharide into the bacterial powder according to the volume ratio of 1:1, and uniformly mixing to obtain the bifidobacterium lactis freeze-dried powder, wherein the strain is named as JYBR-190;
the components of the culture medium are as follows: 10g of peptone, 5g of beef powder, 4g of yeast powder and K2HPO4·7H2O2g, triammonium citrate 2g, sodium acetate 3H2O5 g, glucose 20g, Tween 801 mL, MgSO4·7H2O 0.2g，MnSO4·4H2O0.05 g and distilled water 1000 mL.
Furthermore, the number of live bacteria in the bifidobacterium lactis JYBR-190 freeze-dried powder is more than 50 hundred million/g.
Furthermore, the number of live bacteria in the bifidobacterium lactis JYBR-190 freeze-dried powder is 50 hundred million/g, 150 hundred million/g, 250 hundred million/g, 500 hundred million/g and 1000 hundred million/g.
The invention has the beneficial effects that:
the invention provides bifidobacterium lactis, which has the preservation number as follows: CGMCC NO.18092, the preservation date is 7/8/2019, the strain is named as JYBR-190, the preservation unit is China general microbiological culture Collection center, the preservation address is as follows: west road No.1, north chen, chaoyang district, beijing, zip code: 100101, which belong to the genus Bifidobacterium lactis, i.e. Bifidobacterium animalis subsp. lactococcus lactis, and which are classified in the following units: (ii) Bacteria; actinobacteria; bifidobacteria; bifidobacterium; a bifidobacterium.
The bifidobacterium lactis JYBR-190 provided by the invention has the immunoregulation effect on organisms mainly comprising two aspects of humoral immunity and cellular immunity, and particularly has the effects of activating NK (natural killer) cells and phagocytic cell activity and improving erythrocyte immunoadhesion, so that the immunity of the organisms is improved through humoral immunity, the activated proliferation and secretion of B lymphocytes are improved, the immunity of the organisms is improved through cellular immunity, and the immunity of the organisms of people can be effectively improved.
The food containing the bifidobacterium lactis JYBR-190 freeze-dried powder prepared by the invention can effectively improve the immunity of the organism, reduce the occurrence of diseases and simultaneously has the function of enhancing the physique of the organism.
Drawings
FIG. 1 is a graph showing the effect of different dosages of Bifidobacterium lactis JYBR-190 bacterial liquid on the phagocytic function of mice;
FIG. 2 is a graph showing the effect of different doses of Bifidobacterium lactis JYBR-190 on the spleen weight of mice;
FIG. 3 is a bar graph of the effect of Bifidobacterium lactis JYBR-190 on mouse splenocyte transformation;
the specific implementation mode is as follows:
for better understanding of the present invention, the technical solution of the present invention will be described in detail with specific examples, but the present invention is not limited thereto.
The invention provides bifidobacterium lactis capable of improving human immunity, which has the preservation number as follows: CGMCC NO.18092, the preservation date is 7/8/2019, the strain is named as JYBR-190, the preservation unit is China general microbiological culture Collection center, the preservation address is as follows: west road No.1, north chen, chaoyang district, beijing, zip code: 100101, which are classified as Bifidobacterium lactis (Bifidobacterium lactis), i.e. Bifidobacterium animalis subsp. lactis, and the classification units are: (ii) Bacteria; actinobacteria; bifidobacteria; bifidobacterium; a bifidobacterium.
The control detection strains used in the invention are all commercial food; the isomaltooligosaccharide is purchased from Yongzhao bio-products Co., Ltd;
the genomic DNA kit is purchased from Biotechnology engineering (Shanghai) GmbH;
modified MRS agar medium: adding 5mL of SigmaD-9016 dicloxacillin sodium salt solution, 10mL of Merck No.5679LiCl solution and 5mL of Merck No.2839 cysteine hydrochloride solution into each liter of Difco288210MRS agar culture medium, and uniformly mixing to prepare the MRS agar culture medium;
wherein the SigmaD-9016 sodium dicloxacillin solution (the concentration is 10g/L) is filtered and sterilized by a microporous filter membrane with the aperture of 0.45 mu m;
wherein the MerckNo.5679LiCl solution (concentration is 0.1g/mL) is filtered and sterilized by a 0.45 mu m pore-size microporous filter membrane;
wherein the concentration of MerckNo.2839 cysteine hydrochloride solution is 100 g/L;
LB broth culture medium: 10g of peptone, 5g of sodium chloride and 5g of yeast extract powder, adding distilled water to a constant volume of 1 liter, uniformly mixing, and adjusting the pH value to 7.0 to obtain an LB broth culture medium;
weighing 37.4g of EMB culture medium powder, heating and stirring to dissolve in 1000m1 distilled water, subpackaging into triangular flasks, and autoclaving at 121 deg.C for 15 min;
EC culture medium including tryptone 2g, glucose 2g, yeast extract O.5g, Na2HP040.4g, agar 2g, KH2PO40.4g, and 1OOmL of distilled water; heating to adjust pH to 7.4, autoclaving at 121 deg.C for 15min, cooling to 45-50 deg.C, and adding sodium azide 40 mg;
and (3) weighing 68.9g of BS culture medium powder, sucking 801 ml of Tween, and heating and stirring to dissolve the Tween in 1000m1 distilled water. Sterilizing at 118 deg.C under high pressure for 30min, cooling to 50-55 deg.C, and pouring into a plate;
LBS agar medium is prepared by weighing 84.0g LBS agar, absorbing Tween-801 ml and glacial acetic acid 1.3m1, heating and stirring to dissolve in 1OOOmI distilled water, and using on the same day without autoclaving. Sterilizing at 118 deg.C for 15min for the next day;
RPMI1640 medium was purchased from Gibco;
ConA (containing ConAi6ug/ml) was obtained from Solebao;
1uci3H-TdR was purchased from the national institute of atomic energy;
scintillation fluid was purchased from PE-PerkinElmer, USA;
example 1
The bifidobacterium lactis JYBR-190 capable of improving human immunity
1. Sources of the strains
The sample is derived from naturally fermented yogurt in the home of herdsmen in Ili, Xinjiang;
2. separation and purification of bacterial strain
1) Weighing 5g of naturally fermented yoghourt in Murdan home in Ili, Xinjiang under aseptic condition, adding the yoghourt into 45mL of sterilized normal saline containing glass beads and having the concentration of 0.85%, and uniformly mixing to obtain mother liquor;
2) oscillating the mother liquor for 10 minutes at the rotation speed of 1500 revolutions per minute, taking 1mL of the mother liquor under the aseptic condition, diluting according to 10-fold gradient to form diluent, selecting the diluent with the 7 th, 8 th and 9 th dilution, dropping 0.1mL of the diluent on an improved MRS culture medium plate, uniformly coating, taking two parts of each dilution, taking physiological saline as a blank control group, inversely placing the plate in an anaerobic culture tank, culturing for 72 hours at 37 ℃, and primarily judging to be bifidobacterium lactis when the colony morphology is large and milky white, thereby obtaining a culture strain named as JYBR-190.
3. Strain identification
1) Selecting a universal primer: 27F primer and 1492R primer for later use;
the primer sequence is as follows: 27F: 5'-AGAGTTTGATCMTGGCTCAG-3'
1492R：5'-GGTTACCTTGTTACGACTT-3'
2) Extracting the genome DNA of JYBR-190 by using a genome DNA kit, carrying out PCR amplification on a 16srDNA fragment to obtain an amplification product, sending the amplification product to a biological engineering (Shanghai) corporation for sequencing, detecting the full length of 16SrDNA by sequencing, carrying out Blast comparison in an Eztaxon database, carrying out homology comparison, wherein the strain belongs to Bifidobacterium (animal Bifidobacterium) and is an animal Bifidobacterium lactis species, and the classification unit is as follows: (ii) Bacteria; actinobacteria; bifidobacteria; bifidobacterium; the culture collection center is the common microorganism center of China Committee for culture Collection of microorganisms, the collection number is CGMCC NO.18092, the address of the collection unit is No. 3 Xilu No.1 of Beijing area to the sunny district, and the postal code is as follows: 100101.
example 2
Preparation of bifidobacterium lactis JYBR-190 freeze-dried powder
The preparation method of the bifidobacterium lactis freeze-dried powder comprises the steps of inoculating 1% of bifidobacterium lactis strains into 99% of MRS liquid culture medium according to volume percentage, carrying out anaerobic culture for 24 hours at 37 ℃, taking MRS bacterial liquid, centrifuging and freeze-drying to obtain bacterial powder, adding isomaltooligosaccharide into the bacterial powder according to the volume ratio of 1:1, and uniformly mixing to obtain the bifidobacterium lactis freeze-dried powder, wherein the bacterial strain is named as JYBR-190, and the viable count of the bifidobacterium lactis JYBR-190 freeze-dried powder is 50 hundred million/g, 150 hundred million/g, 250 million/g, 500 hundred million/g and 1000 million/g.
EXAMPLE 3
Effect of Bifidobacterium lactis JYBR-190 on mouse cellular immunity
1. Preparation of bacterial liquid
Inoculating Bifidobacterium lactis JYBR-190 strain in LB broth culture medium, anaerobically culturing at 37 deg.C for 24 hr, collecting 10ml of the culture solution, washing with sterile PBS buffer solution for 3 times, and adjusting the culture solution to 10 with McLeod's turbidimetry7CFU/mL、108CFU/mL、109CFU/mL、1010CFU/mL to obtain 107CFU/mL Bifidobacterium lactis JYBR-190 bacterial liquid and 108CFU/mL Bifidobacterium lactis JYBR-190 bacterial liquid and 109CFU/mL Bifidobacterium lactis JYBR-190 bacterial liquid and 1010A CFU/mL Bifidobacterium lactis JYBR-190 bacterial liquid for later use;
2. carbon particle clearance test
① selecting 50 mice with weight of 20g, evenly dividing the mice into 5 groups, namely a PBS control group, a test group 1, a test group 2, a test group 3 and a test group 4, wherein each group comprises 10 mice for standby;
test group 1 intraperitoneal injection of 5ml of 10 per day7The CFU/mL Bifidobacterium lactis JYBR-190 bacterial liquid is injected for 4 days 1 time per day;
test group 3 intraperitoneal injection of 5ml of 10 per day9The CFU/mL Bifidobacterium lactis JYBR-190 bacterial liquid is injected for 4 days 1 time per day;
test group 4 intraperitoneal injection of 5ml of 10 per day10The CFU/mL Bifidobacterium lactis JYBR-190 bacterial liquid is injected for 4 days 1 time per day;
injecting 5ml of normal saline into the abdominal cavity of the PBS control group every day for 1 time every day for 4 days;
② diluting the ink with physiological saline solution 4 times, injecting the diluted ink into mice via tail vein at a dose of 0.2 ml/mouse, collecting blood at eye orbit for 25ul at 2min, 10min, 20min, and 30min after the diluted ink is injected, adding the blood sample into 2ml of 0.1% sodium carbonate solution, measuring OD at 650nm wavelength with microplate reader, calculating phagocytosis index K, killing the mice by removing neck, weighing spleen, and calculating spleen weight (mg)/body weight (g), with the results shown in Table 1, FIG. 1, and FIG. 2
K＝logOD1-logOD2/T2-T1
As a result:
TABLE 1 Effect of Bifidobacterium lactis JYBR-190 on mouse carbon clearance
Note: 1.. P < 0.05. P < 0.001
As shown in Table 1, after the bifidobacterium JYBR-190 bacterial liquid is injected into the abdominal cavity of a mouse, the clearance speed of carbon granules in blood is obviously accelerated.
At 2min, compared with the PBS group, the retention amount of carbon granules in blood is relatively reduced, at 20min, compared with the PBS group, the carbon granules are basically clear, and at 30min, the carbon concentration in the blood of the PBS group is still obviously higher than that of the test group;
as shown in figure 1, the phagocytic capacity of the mice to the carbon granules is gradually increased with the increase of the dosage of JYBR-190.
As shown in fig. 2: the influence of the bifidobacterium lactis JYBR-190 on the spleen weight of a mouse is measured after the bifidobacterium lactis JYBR-190 bacterial liquid is injected into the abdominal cavity of the mouse, the number of milligrams of the spleen contained in each gram of the body weight is calculated, and the result shows that the spleen weight of the mouse is remarkably increased after the bifidobacterium lactis JYBR-190 bacterial liquid is injected into the abdominal cavity, and the spleen weight is more remarkably increased along with the increase of the injection dosage.
3. Lymphocyte transformation assay
1) Decapitation C57BL mice, taking mouse spleen, grinding, filtering with 200 mesh filter screen, adding erythrocyte lysate, cracking for 10min, centrifuging, resuspending with PBS, and preparing C57BL mice spleen cell suspension, and trypan blue exclusion method to determine cell viability (dead cells will be stained blue), adjusting cell concentration to 8X108Per mL, dividing the mouse spleen cell suspension into 9 parts on average for later use;
2) preparation of Bifidobacterium lactis JYBR-190 bacterial suspension
The number of viable bacteria is 5 multiplied by 104Taking CFU/ml Bifidobacterium lactis JYBR-190 bacterial suspension as an example, according to the viable count requirement, taking Bifidobacterium lactis JYBR-190 freeze-dried powder and PBS buffer solution, mixing uniformly to prepare the Bifidobacterium lactis JYBR-190 bacterial suspension with the viable count of 5 multiplied by 104CFU/ml of Bifidobacterium lactis JYBR-190 bacterial suspension;
according to the viable count of 5 multiplied by 104Preparation method of CFU/ml Bifidobacterium lactis JYBR-190 bacterial suspension, sequentially preparing viable count of 5 × 107The viable count of the suspension of the CFU/ml bifidobacterium lactis JYBR-190 is 5 multiplied by 108The viable count of the suspension of the CFU/ml bifidobacterium lactis JYBR-190 is 5 multiplied by 109CFU/ml Bifidobacterium lactis JYBR-190 bacterial suspension, wherein the preparation method only needs to adjust the adding amount of Bifidobacterium lactis JYBR-190 lyophilized powder and PBS buffer solution to respectively prepare the suspension with viable count of 5 × 107The viable count of the suspension of the CFU/ml bifidobacterium lactis JYBR-190 is 5 multiplied by 108The viable count of the suspension of the CFU/ml bifidobacterium lactis JYBR-190 is 5 multiplied by 109CFU/ml of Bifidobacterium lactis JYBR-190 bacterial suspension;
3) preparation of bacterial liquid to be detected
The number of viable bacteria is 5 multiplied by 104To-be-detected bacterium liquid of CFU/ml bifidobacterium lactis JYBR-190
Taking C in the step 1)57Adding 100uL of BL mouse spleen cell suspension into a 96-well plate, and adding 5 multiplied by 10 viable bacteria into each well4CFU/ml Bifidobacterium lactis JYBR-190 suspension 50ul, and finally culturing with RPMI1640 cellsBase supplementation to a total volume of 200uL per well, 96-well plates were placed in 5% CO2Culturing at 37 deg.C for 56 hr, adding 1uci into each well3H-TdR, continued at 5% CO2Culturing at 37 deg.C for 72 hr, collecting cells in 96-well plate, placing on 49-type glass fiber filter paper, drying, adding scintillation liquid (the addition amount is in accordance with the specification), and making into 5 × 10 viable bacteria4CFU/ml of to-be-detected bacterial liquid of bifidobacterium lactis JYBR-190;
according to the viable count of 5 multiplied by 104Preparation method of CFU/ml bacterial liquid to be detected of bifidobacterium lactis JYBR-190, sequentially preparing bacterial liquid with viable count of 5 multiplied by 107CFU/ml of Bifidobacterium lactis JYBR-190 to-be-detected bacterial liquid with viable count of 5 multiplied by 108CFU/ml of Bifidobacterium lactis JYBR-190 to-be-detected bacterial liquid with viable count of 5 multiplied by 109CFU/ml of to-be-detected bacterial liquid of bifidobacterium lactis JYBR-190, wherein in the preparation method, only the suspension of bifidobacterium lactis JYBR-190 with different viable counts needs to be adjusted, and the rest is the same;
the number of viable bacteria is 5 multiplied by 104Preparation of CFU/ml Bifidobacterium lactis JYBR-190+ ConA mixed bacterial liquid to be detected
C in step 1)57Adding 100uL of BL mouse spleen cell suspension into a 96-well plate, and adding 5 multiplied by 10 viable bacteria into each well4CFU/ml of Bifidobacterium lactis JYBR-190 suspension 50uL and 50uL of ConA (containing Conai6ug/ml), and finally supplemented with RPMI1640 cell culture medium to make the total volume of each well 200uL, placing 96-well plate in 5% CO2Culturing at 37 deg.C for 56 hr, adding 1uci into each well3H-TdR, continued at 5% CO2Culturing at 37 deg.C for 72 hr, collecting cells in 96-well plate, placing on 49-type glass fiber filter paper, drying, adding scintillation liquid (the addition amount is in accordance with the specification), and making into 5 × 10 viable bacteria4CFU/ml of Bifidobacterium lactis JYBR-190+ ConA mixed bacterial liquid to be detected;
according to the viable count of 5 multiplied by 104Preparation method of CFU/ml Bifidobacterium lactis JYBR-190+ ConA mixed bacterial liquid to be detected, sequentially preparing bacterial liquid with viable count of 5 × 107CFU/ml of Bifidobacterium lactis JYBR-190+ ConA mixed bacterial liquid to be detected, the viable count is5×108CFU/ml Bifidobacterium lactis JYBR-190+ ConA mixed bacterial liquid to be detected, the viable count is 5 multiplied by 109CFU/ml of Bifidobacterium lactis JYBR-190+ ConA mixed bacterial liquid to be detected, wherein in the preparation method, only the Bifidobacterium lactis JYBR-190 bacterial suspension with different viable counts needs to be adjusted, and the others are the same;
wherein the bacterial suspension in the control group 1 is replaced by normal saline;
4) determination of cell incorporation in each group of bacterial liquid to be detected by Beckman liquid scintillation instrument3Hcpm values, the effect of Bifidobacterium lactis JYBR-190 on mouse spleen lymphocyte transformation are shown in FIG. 3;
as can be seen from fig. 3: when JYBR-190 alone was mixed with mouse spleen lymphocytes and cultured, the spleen cells were in-vivo compared with the control group (not shown in the figure because the control group data was 0)3The doping amount of H-TdR is obviously increased, the dosage of JYBR-190 is different, the stimulation degree to splenocytes is also different, wherein the JYBR-190 bacterium concentration is 108The stimulation effect of CFU/well is maximal, greater than the stimulation index of ConA (0.8 ug/well, i.e. final concentration 4 ug/ml); in addition, when different concentrations of bifidobacterium lactis JYBR-190 and ConA were simultaneously mixed with splenocytes for culture, the stimulation index of both splenocytes was greater than that when both were used alone, summarizing: the bifidobacterium lactis JYBR-190 can nonspecifically activate macrophages and enhance the transformation function of lymphocytes.
Example 4
Effect of Bifidobacterium on humoral immunity in mice
1. Detection of intestinal flora in mice
1) Materials and methods
Selecting 30 mice with the age of 8 weeks and the weight of 18-22g, wherein the mice are half female and half male, and are averagely divided into 2 groups, namely a control group 2 and a bifidobacterium lactis JYBR-190 group, and each group comprises 15 mice;
respectively selecting an EMB culture medium, an EC culture medium, a BS culture medium and an LBS culture medium, wherein the EMB culture medium is used for culturing and separating enterobacteria, the EC culture medium is used for culturing and separating enterococci, the BS culture medium is used for culturing and separating bifidobacteria and the LBS culture medium is used for culturing and separating lactobacillus;
2) test method
Bifidobacterium lactisBacillus JYBR-190 mice are inoculated with Bifidobacterium lactis JYBR-190 bacterial liquid every day (the viable count of the bacterial liquid is 10)9CFU/ml), 1 time/day, 5 ml/time, and continuous gavage for 10 days; control group 2 mice were killed by decapitation method after 10 days by feeding equivalent physiological saline every day for 1 time/day for 10 consecutive days, cecum contents were taken and inoculated in an EMB medium, an EC medium, a BS medium, and an LBS medium according to an inoculum size of 1% by volume, anaerobic culture was carried out for 48-72 hours (mainly, culture separation of bifidobacteria, lactobacilli, enterobacteria, and enterococci was carried out on the cecum contents), colony characteristics in each medium (the colony characteristics of bifidobacteria were smooth and convex on the medium, the edge was complete, milky, glossy, and soft; the colony characteristics of lactobacilli were medium-sized, convex, whitish, moist, the edge was neat, the colony characteristics of enterobacteria were purple, the colony characteristics of enterococci were gram-positive, round or oval, about 0.5-1.0 μm in diameter, no spores, single, double or short chain arrangement, milky round colonies, wet and smooth surface, regular edges, 1-2mm in diameter, gram staining of characteristic colonies, and counting of colonies (Log colony forming units/g CFU/g), the results are shown in table 2.
TABLE 2 Effect of Bifidobacterium lactis JYBR-190 on normal intestinal flora in mice
As shown in Table 2, the bacterial liquid of Bifidobacterium lactis JYBR-190 after the gavage was 10 days was compared with the control group 2. The bacterial numbers of enterobacteria, enterococcus, bifidobacteria and lactobacillus in the normal intestinal flora of the mice in the group of the Bifidobacterium lactis JYBR-190 are obviously reduced.
2. Hemolytic plaque assay (PFC) assay
1) Materials and methods
Selecting 10 mice with the age of 8 weeks and the weight of 18-22g, and averagely dividing the mice into 2 groups, namely a control group 3 and a bifidobacterium lactis JYBR-190 group, wherein each group comprises 15 mice;
2) test method
Preparation method of spleen cell suspension
Preparation method for preparing bifidobacterium lactis JYBR-190 group spleen cell suspension by taking bifidobacterium lactis JYBR-190 as example
Bifidobacterium lactis JYBR-190 mice perfused with Bifidobacterium lactis JYBR-190 bacterial liquid every day (the viable count of the bacterial liquid is 10)9CFU/ml) for 1 time every day, 5ml every time, feeding for 6 days continuously, then injecting 400uL sheep red blood cells into the abdominal cavity for immunization, injecting for 4 days continuously, taking out the neck to kill the mouse, taking out the spleen, grinding the spleen, washing the spleen twice by PBS (phosphate buffer solution), then adding 6 parts of PBS into 1 part of the spleen according to the weight part ratio of 1:6, and uniformly mixing to form a spleen cell suspension of the Bifidobacterium lactis JYBR-190 group;
preparing a control group spleen cell suspension according to a preparation method of the bifidobacterium lactis JYBR-190 group spleen cell suspension, wherein the bifidobacterium lactis JYBR-190 bacterial liquid in a control group 3 is replaced by the same amount of normal saline, and other preparation methods are the same;
test treatment
Taking the spleen cell suspension of one mouse in the spleen cell suspension of the bifidobacterium lactis JYBR-190 group as an example to calculate the number of hemolytic plaques: sequentially adding 50 mu L of guinea pig complement, 180 mu L of PBS (phosphate buffer solution), 50 mu L of sheep red blood cell with the concentration of 10% and 20 mu L of spleen cell suspension into each hole in a 24-hole plate, uniformly mixing, sealing, incubating for 1.5h at 37 ℃, and observing the number of plaques in the 24-hole plate;
according to the method for calculating the number of the hemolytic plaques of the spleen cell suspension of one mouse in the Bifidobacterium lactis JYBR-190 group, the average number of the hemolytic plaques of the spleen cell suspension of other mice in the Bifidobacterium lactis JYBR-190 group and the average number of the hemolytic plaques of the spleen cell suspension of the control group are calculated in sequence, and the results are shown in Table 3;
3. spleen weighing calculation
1) Materials and methods
Selecting 10 mice with the age of 8 weeks and the weight of 18-22g, and averagely dividing the mice into 2 groups, namely a control group 4 and a bifidobacterium lactis JYBR-190 group, wherein each group comprises 15 mice;
2) test method
Taking one mouse of bifidobacterium lactis JYBR-190 as an example to calculate the weight of the spleen of the mice of bifidobacterium lactis JYBR-190 group
Bifidobacterium lactis JYBR-190 mice perfused with Bifidobacterium lactis JYBR-190 bacterial liquid every day (the viable count of the bacterial liquid is 10)9CFU/ml) 1 time a day, 5ml each time, feeding for 10 days continuously, removing neck, killing mice, taking out spleen, soaking in 75% alcohol for 2min, taking out spleen, and weighing;
according to the processing method of spleen of one mouse in Bifidobacterium lactis JYBR-190 group, spleen of other mice in Bifidobacterium lactis JYBR-190 group is processed and weighed in turn, spleen of each mouse in control group 4 is processed at the same time to obtain spleen, weighing is carried out, average value is calculated, the result is shown in Table 4,
TABLE 3 Effect of Bifidobacterium lactis JYBR-190 on hemolytic plaque
| Control group 3 | Bifidobacterium lactis JYBR-190 group | P | |
| Number of plaques (/ spleen) | 462.020±35.670 | 236.630±30.624 | <0.01 |
| Spleen | 0.124±0.07 | 0.093±0.012 | <0.01 |
As shown in Table 3, the number of hemolytic plaques and the weight of spleen of splenocytes of mice in Bifidobacterium lactis JYBR-190 group were significantly lower than those of normal control group.
TABLE 4 analysis of the correlation between Bifidobacterium lactis and the immunological index
| r (correlation index) | P | |
| Number of plaques (/ spleen) | 0.957 | <0.01 |
| Spleen | 0.825 | <0.01 |
As shown in Table 4, the number of Bifidobacterium lactis JYBR-190 was significantly and positively correlated with the number of hemolytic plaque cells and the weight of spleen; the number of the bifidobacterium lactis JYBR-190 is obviously and positively correlated with the number of the hemolytic plaque cells and the weight of the spleen.
In immunology, the body is stimulated by foreign antigens to activate B lymphocytes into activated B cells, which are then differentiated into plasma cells through proliferation, antigen selection, immunoglobulin type conversion, changes in certain markers on the cell surface and somatic mutations, at which time the body produces high-affinity antibodies, which can perform humoral immunity. Therefore, the number of cells formed by the antibody can reflect the humoral immunity state of the body. The number of antibody-forming cells is often measured by a hemolytic plaque assay, and it is found that a reduction in the number of hemolytic plaques in the mouse splenocyte suspension following dysbacteriosis indicates a reduction in cells capable of releasing anti-SRBC antibodies, i.e., a reduction in antibody-forming cells, indicating a lack of normal flora as an antigenic stimulant, a reduction in activated B cells, and a reduction in the humoral immune function of the body.
The spleen is a place where various immune cells live, and is also an important base for generating immune response to foreign antigen substances and immune effector substances (such as antibodies and the like). Foreign scholars find that the bifidobacterium lactis can promote the weight increase of the spleen of a mouse, the proliferation of splenocytes, the transformation of B lymphocytes and the like. After weighing spleens of mice treated by bifidobacterium lactis JYBR-190, the spleen weight of mice with dysbacteriosis is found to be obviously lower than that of normal mice, which shows that spleen development of peripheral immune organs is atrophied due to lack of stimulation of normal flora as an immunogenic substance, and normal immune functions cannot be executed.
The bifidobacterium lactis is beneficial bacteria with the largest content in intestinal tracts of organisms, has the effects of biological barrier action, intestinal flora adjustment, nutritional function enhancement, immunity enhancement, tumor resistance and the like, and is one of important signs of human health. The bifidobacterium lactis is subjected to correlation analysis with the number of hemolytic plaque cells and the weight of spleen serving as immune indexes, and the bifidobacterium is found to have obvious positive correlation with the bifidobacterium, so that the bifidobacterium lactis JYBR-190 plays an important role in regulating the humoral immunity of an organism.
Example 5
The lactobacillus beverage is prepared by taking bifidobacterium lactis JYBR-190 freeze-dried powder as a main material, and the steps are as follows:
1) adding 2 parts of lily, 10.1 parts of vitamin B, 20.1 parts of vitamin B, 60.1 parts of vitamin B, 120.1 parts of vitamin B, 0.1 part of vitamin C, 0.5 part of lysine, 0.5 part of methionine, 6 parts of collagen, 5 parts of dietary fiber, 2 parts of lecithin, 0.15 part of zinc, 0.15 part of iron, 0.4 part of folic acid and 2 parts of skim milk powder into 50 parts of water by weight, and uniformly mixing to prepare a mixed solution I;
2) adding 0.7 part of citric acid, 0.5 part of pectin and 1 part of sodium alginate into the mixed solution I according to the parts by weight, uniformly mixing, and boiling for 10 minutes to prepare a mixed solution II;
3) adding 5 parts of bifidobacterium lactis JYBR-190 freeze-dried powder, 2 parts of honey and 1 part of enzyme preparation into the mixed solution II according to the parts by weight, uniformly mixing, and subpackaging to obtain a finished product;
the viable count of the bifidobacterium lactis JYBR-190 in the lactobacillus beverage is 250 hundred million/g.
Example 6
The lactobacillus granules are prepared by taking bifidobacterium lactis JYBR-190 freeze-dried powder as a main material, and the steps are as follows:
1) adding 2 parts of lily, 10.1 parts of vitamin B, 20.1 parts of vitamin B, 60.1 parts of vitamin B, 120.1 parts of vitamin B, 0.1 part of vitamin C, 0.5 part of lysine, 0.5 part of methionine, 5 parts of collagen, 3 parts of dietary fiber, 2 parts of lecithin, 0.15 part of zinc, 0.15 part of iron, 0.5 part of folic acid and 2 parts of skim milk powder into 8 parts of water by weight, and uniformly mixing to prepare a mixture I;
2) adding 0.5 part of citric acid, 0.5 part of pectin and 1 part of sodium alginate into the mixed solution I according to the parts by weight, uniformly mixing, and boiling for 10 minutes to prepare a mixture II;
3) adding 8 parts of bifidobacterium lactis JYBR-190 freeze-dried powder, 5 parts of honey and 1 part of enzyme preparation into the mixture II according to the parts by weight, uniformly mixing, sieving, and forming lactobacillus granules by a granulator;
the viable count of the bifidobacterium lactis JYBR-190 in the lactobacillus granules is 1000 hundred million/g.
Comparative example 1
The difference between the comparative example 1 and the example 6 is that the freeze-dried powder of the bifidobacterium lactis JYBR-190 is lacked, and other technical characteristics are the same.
Comparative example 2
The difference between the comparative example 2 and the example 6 is that the freeze-dried powder of the bifidobacterium lactis JYBR-190, lysine amino acid, methionine and collagen are lacked, and other technical characteristics are the same.
Experiment 1 experiment of using food containing bifidobacterium lactis JYBR-190 freeze-dried powder in improving immunity of organism
The source of the test member: the old male aged 70 years old are cold early-healing patients, each group comprises 5 persons, 7 groups are divided into 2 test groups, 1 blank group and 4 comparison groups, the test groups take 10G/day of lactobacillus food in examples 5-6, the comparison group 1 takes 10G/day of food in the comparison group 1, the comparison group 2 takes 10G/day of food in the comparison group 2, the comparison group 3 takes 10G/day of oral decoction ministerial double-health protein powder (health food (food healthy character) G20140134 purchased from Kyoto Shanghai city), the comparison group 4 takes 10 ml/day of oral Beijing Hojingtang royal jelly oral liquid (health food (food healthy character) G200736 purchased from Kyoto Shanghai city), the blank group takes 200 ml/day for 1 month continuously, and then five immune items (including IgA, IgD, IgE, IgG and IgM) of members in each group are detected, complement detection (including complement C3), C4) And recording the results, and the results are shown in the table;
table 5: examples 5-6, comparative groups 1-3, and blank groups for the test of enhancing immunity
| Group of | IgA | IgD | IgE | IgG | IgM | Complement C3 | Complement C4 |
| Example 5 | 2.4±0.2 | 15.3±0.1 | 1.4±0.3 | 13.2±0.4 | 2.2±0.1 | 654.32±23.10 | 55.32±4.6 |
| Example 6 | 3.1±0.5 | 16.5±0.3 | 1.9±0.4 | 15.6±0.7 | 2.5±0.4 | 712.12±71.32 | 58.32±3.6 |
| Comparative group 1 | 1.4±0.5 | 14.1±0.4 | 0.9±0.1 | 11.0±0.1 | 1.0±0.3 | 531.32±23.12 | 51.12±3.6 |
| |
1.3±0.4 | 13.4±0.6 | 0.8±0.4 | 10.2±0.3 | 1.5±0.4 | 435.62±32.16 | 53.32±6.5 |
| Comparative group 3 | 1.6±0.2 | 12.2±0.6 | 0.8±0.4 | 9.5±0.4 | 0.9±0.4 | 466.34±23.21 | 50.23±4.5 |
| Comparative group 4 | 1.4±0.6 | 13.3±0.4 | 0.9±0.4 | 9.7±0.6 | 0.9±0.7 | 543.35±12.35 | 53.21±2.5 |
| Blank group | 0.8±0.2 | 11.8±0.2 | 0.5±0.3 | 7.5±0.3 | 0.6±0.4 | 375.45±46.01 | 50.31±6.35 |
As shown in Table 5, the food prepared by the invention can effectively improve the immunity of the organism.
SEQUENCE LISTING
<110> Shandong Zhongke Jiayi bioengineering Co., Ltd
<120> bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicine
<130>2019
<160>3
<170>PatentIn version 3.3
<210>1
<211>950
<212>DNA
<213> Bifidobacterium lactis
<400>1
ggcccgggaa cgcattcacc gcggcgttgc tgatccgcga ttactagcga ctccgccttc 60
acgcagtcga gttgcagact gcgatccgaa ctgagaccgg ttttcagcga tccgccccac 120
gtcaccgtgt cgcacgcgtt gtaccggcca ttgtagcatg cgtgaagccc tggacgtaag 180
gggcatgatg atctgacgtc atccccacct tcctccgagt tgaccccggc ggtcccacat 240
gagttcccgg catcacccgc tggcaacatg cggcgagggt tgcgctcgtt gcgggactta 300
acccaacatc tcacgacacg agctgacgac gaccatgcac cacctgtgaa ccggccccga 360
agggaaaccg tgtctccacg gcgatccggc acatgtcaag cccaggtaag gttcttcgcg 420
ttgcatcgaa ttaatccgca tgctccgccg cttgtgcggg cccccgtcaa tttctttgag 480
ttttagcctt gcggccgtac tccccaggcg ggatgcttaa cgcgttggct ccgacacggg 540
acccgtggaa agggccccac atccagcatc caccgtttac ggcgtggact accagggtat 600
ctaatcctgt tcgctcccca cgctttcgct cctcagcgtc agtgacggcc cagagacctg 660
ccttcgccat tggtgttctt cccgatatct acacattcca ccgttacacc gggaattcca 720
gtctccccta ccgcactcca gcccgcccgt acccggcgca gatccaccgt taggcgatgg 780
actttcacac cggacgcgac gaaccgccta cgagcccttt acgcccaata aatccggata 840
acgctcgcac cctacgtatt accgcggctg ctggcacgta gttagccggt gcttattcga 900
acaatccact caacacggcc gaaaccgtgc cttgcccttg aacaaaagcg 950
<210>2
<211>20
<212>DNA
<213> Artificial Synthesis
<400>2
agagtttgat cmtggctcag 20
<210>3
<211>19
<212>DNA
<213> Artificial Synthesis
<400>3
ggttaccttg ttacgactt 19
Claims (9)
1. A Bifidobacterium lactis JYBR-190 capable of improving human immunity is characterized in that the deposit number of the Bifidobacterium lactis is as follows: CGMCC NO.18092, the preservation date is 7/8/2019, the strain is named as JYBR-190, the preservation unit is China general microbiological culture Collection center, the preservation address is as follows: west road No.1, north chen, chaoyang district, beijing, zip code: 100101.
2. the application of the bifidobacterium lactis JYBR-190 for improving human immunity in preparing food and medicines according to claim 1.
3. The use according to claim 2, wherein the food or pharmaceutical product is used for enhancing immunity.
4. The use according to claim 2 or 3, wherein the food or pharmaceutical product is a food or pharmaceutical product having the deposit number of claim 1: the Bifidobacterium lactis JYBR-190 with the molecular weight of CGMCC NO.18092 is prepared.
5. The use according to claim 2 or 3, wherein the food or pharmaceutical product has the effects of increasing NK cell activity and phagocyte activity, increasing red blood cell immunoadhesion, and increasing activated proliferation and secretion of B lymphocytes.
6. The use according to claim 2 or 3, wherein the food or pharmaceutical product comprises a lyophilized powder of Bifidobacterium lactis JYBR-190.
7. The application of claim 6, wherein the bifidobacterium lactis JYBR-190 freeze-dried powder is prepared by inoculating 1% of bifidobacterium lactis strains into 99% of MRS liquid culture medium by volume percentage, carrying out anaerobic culture at 37 ℃ for 24 hours, taking MRS bacterial liquid, centrifuging and freeze-drying to obtain bacterial powder, adding isomaltooligosaccharide into the bacterial powder according to the volume ratio of 1:1, and uniformly mixing to obtain bifidobacterium lactis freeze-dried powder, wherein the strain is named as JYBR-190;
the components of the culture medium are as follows: 10g of peptone, 5g of beef powder, 4g of yeast powder and K2HPO4·7H2O2g, triammonium citrate 2g, sodium acetate 3H2O5 g, glucose 20g, Tween 801 mL, MgSO4·7H2O 0.2g，MnSO4·4H2O0.05 g and distilled water 1000 mL.
8. The application of claim 7, wherein the number of viable bacteria in the lyophilized powder of Bifidobacterium lactis JYBR-190 > 50 hundred million/g.
9. The use of claim 8, wherein the number of viable bacteria in the lyophilized powder of bifidobacterium lactis JYBR-190 is 50 hundred million/g, 150 hundred million/g, 250 hundred million/g, 500 hundred million/g, or 1000 hundred million/g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911164456.0A CN110846253A (en) | 2019-11-25 | 2019-11-25 | Bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911164456.0A CN110846253A (en) | 2019-11-25 | 2019-11-25 | Bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110846253A true CN110846253A (en) | 2020-02-28 |
Family
ID=69604175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911164456.0A Pending CN110846253A (en) | 2019-11-25 | 2019-11-25 | Bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110846253A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112940989A (en) * | 2021-04-16 | 2021-06-11 | 吉林大学 | Complex microbial inoculant with intelligence-developing function and preparation method and application thereof |
| CN113262242A (en) * | 2021-07-16 | 2021-08-17 | 山东中科嘉亿生物工程有限公司 | Application of bifidobacterium lactis JYBR-190 in removing in-vivo heavy metal products |
| CN115505543A (en) * | 2022-09-28 | 2022-12-23 | 天津小薇生物科技有限公司 | Bifidobacterium lactis BR001, fermentation method thereof and application of bifidobacterium lactis BR001 in improving allergy |
| CN116445356A (en) * | 2023-04-28 | 2023-07-18 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof |
| CN116569999A (en) * | 2023-05-09 | 2023-08-11 | 沈阳农业大学 | Fermentation method of blueberry juice |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108220193A (en) * | 2018-01-08 | 2018-06-29 | 金华银河生物科技有限公司 | One plant of bifidobacterium lactis, a kind of bifidobacterium lactis freeze-dried powder and preparation method thereof |
| CN109055278B (en) * | 2018-09-17 | 2019-09-06 | 山东中科嘉亿生物工程有限公司 | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application |
| CN110452842A (en) * | 2019-08-01 | 2019-11-15 | 诺佰克（武汉）生物科技有限公司 | Bifidobacterium lactis nbk-W13 and its application |
-
2019
- 2019-11-25 CN CN201911164456.0A patent/CN110846253A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108220193A (en) * | 2018-01-08 | 2018-06-29 | 金华银河生物科技有限公司 | One plant of bifidobacterium lactis, a kind of bifidobacterium lactis freeze-dried powder and preparation method thereof |
| CN109055278B (en) * | 2018-09-17 | 2019-09-06 | 山东中科嘉亿生物工程有限公司 | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application |
| CN110452842A (en) * | 2019-08-01 | 2019-11-15 | 诺佰克（武汉）生物科技有限公司 | Bifidobacterium lactis nbk-W13 and its application |
Non-Patent Citations (2)
| Title |
|---|
| 张泽全等: "《糖尿病治疗新概念》", 31 January 2008 * |
| 朱大诚等: "《生理学实验教程（第2版）》", 31 December 2014 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112940989A (en) * | 2021-04-16 | 2021-06-11 | 吉林大学 | Complex microbial inoculant with intelligence-developing function and preparation method and application thereof |
| CN112940989B (en) * | 2021-04-16 | 2021-09-03 | 吉林大学 | Complex microbial inoculant with intelligence-developing function and preparation method and application thereof |
| CN113262242A (en) * | 2021-07-16 | 2021-08-17 | 山东中科嘉亿生物工程有限公司 | Application of bifidobacterium lactis JYBR-190 in removing in-vivo heavy metal products |
| CN113262242B (en) * | 2021-07-16 | 2021-11-05 | 山东中科嘉亿生物工程有限公司 | Application of bifidobacterium lactis JYBR-190 in removing in-vivo heavy metal products |
| CN115505543A (en) * | 2022-09-28 | 2022-12-23 | 天津小薇生物科技有限公司 | Bifidobacterium lactis BR001, fermentation method thereof and application of bifidobacterium lactis BR001 in improving allergy |
| CN115505543B (en) * | 2022-09-28 | 2024-01-26 | 天津小薇生物科技有限公司 | Bifidobacterium lactis BR001, fermentation method thereof and application thereof in improving allergy |
| CN116445356A (en) * | 2023-04-28 | 2023-07-18 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof |
| CN116445356B (en) * | 2023-04-28 | 2024-01-30 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof |
| CN116569999A (en) * | 2023-05-09 | 2023-08-11 | 沈阳农业大学 | Fermentation method of blueberry juice |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110846253A (en) | Bifidobacterium lactis JYBR-190 capable of improving human immunity and application thereof in food and medicine | |
| CN101260377B (en) | Animal bifidobacteria and use thereof | |
| CN100489086C (en) | Lactic acid bacteria capable of stimulating mucosal immunity | |
| CN110964657B (en) | Bifidobacterium lactis BL-99 capable of improving immunity and application thereof | |
| CN110179121A (en) | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application | |
| CN111548970B (en) | Lactobacillus crispatus capable of preventing and/or treating helicobacter pylori infection | |
| CN104498383B (en) | A kind of lactobacillus fermenti Lactobacillus fermentum strain suo and application thereof of adjustable intestinal movement, Constipation | |
| CN107164263A (en) | A kind of adjustable function of intestinal canal, the lactobacillus fermenti HY01 for preventing colitis and application thereof | |
| CN114381411B (en) | Lactococcus lactis JYLL-60 and application thereof in preparation of product for improving immunity | |
| CN110484459B (en) | Lactobacillus plantarum and application thereof | |
| CN109588726B (en) | Lactobacillus casei composition for improving sleep and preparation method thereof | |
| CN114480229A (en) | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof | |
| CN114908020B (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application of lactobacillus plantarum in edible herbal enzyme product | |
| CN114672445A (en) | Lactobacillus rhamnosus strain LRa90, application thereof in preparation of product for treating allergy and/or inhibiting pathogenic bacteria, and product | |
| CN101328468A (en) | Antiallergic lactic acid bacteria | |
| CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
| CN116024131B (en) | Lactobacillus plantarum strain GOLDGUT-LP101 and application thereof | |
| CN115093999B (en) | Clostridium praecox capable of improving blood lipid disorders and application thereof | |
| CN113142301A (en) | Dairy product capable of improving immunity of organism and preparation method thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN114540243A (en) | Lactobacillus rhamnosus capable of preventing and/or treating helicobacter pylori infection and application thereof | |
| CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
| CN111743158B (en) | Probiotic tablet with function of enhancing immunity and preparation method thereof | |
| CN111728030B (en) | Sucrose-free yogurt with immunity improving function and long shelf life at normal temperature and preparation method thereof | |
| CN111685255B (en) | Probiotic solid beverage for enhancing immune function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200228 |
|
| RJ01 | Rejection of invention patent application after publication |